After two weeks of treatment, GZR18 tablets resulted in an average weight reduction of up to 4.16%, with continued weight loss observed even after discontinuation. The pharmacokinetic profile supports a once-daily oral dosing regimen for GZR18 tablets. The safety and tolerability of GZR18 tablets align with the known safety characteristics of GLP-1 receptor agonists, with no unexpected safety signals during the study.BEIJING, Nov. 12, 2024 /PRNewswire/ -- Gan & Lee Pharmaceuticals (Gan & Lee, Shanghai Stoc ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-32593 Global Partners LP (Exact name of registrant as specified in its charter) Delaware 74-3140887 (State o ...

Global Partners LP Common Units (NYSE:GLP) Q3 2024 Earnings Conference Call November 8, 2024 10:00 AM ET Company Participants Eric Slifka - President & CEO Gregory Hanson - CFO Mark Romaine - COO Sean Geary - CLO & Secretary Conference Call Participants Selman Akyol - Stifel Operator Good day, everyone, and welcome to the Global Partners Third Quarter 2024 Financial Results Conference Call. Today's call is being recorded. [Operator Instructions]. With us from Global Partners are President and Chief Executiv ...

FOR IMMEDIATE RELEASE Contacts: PRESS RELEASE Exhibit 99.1 GLOBAL PARTNERS LP 800 South Street, Suite 500 P.O. Box 9161 Waltham, MA 02454-9161 www.globalp.com Gregory B. Hanson Sean T. Geary Chief Financial Officer Chief Legal Officer and Secretary Global Partners LP Global Partners LP (781) 894-8800 (781) 894-8800 Global Partners Reports Third-Quarter 2024 Financial Results Waltham, Mass., November 8, 2024 – Global Partners LP (NYSE: GLP) ("Global" or the "Partnership") today reported financial results for ...

Though the stock market has raced to fresh all-time highs over the past month, the mood is anything but complacent as we head toward a potentially fractious election amid an uncertain macroeconomy. And one of the most volatileWith combined experience of covering technology companies on Wall Street and working in Silicon Valley, and serving as an outside adviser to several seed-round startups, Gary Alexander has exposure to many of the themes shaping the industry today. He has been a regular contributor on S ...

Preclinical data from ex vivo human islet experiments showed that icovamenib (BMF-219) was able to enhance the activity of glucagon-like peptide-1 (GLP-1)-based therapies, potentially leading to increased insulin secretion and improved glycemic control in patients with diabetes Phase II study (COVALENT-211), combining icovamenib with a GLP-1-based therapy, planned to begin in 2025 BMF-650, an investigational next-generation, oral small-molecule GLP-1 receptor agonist (GLP-1 RA), demonstrated positive early ...

Novo Nordisk dominates diabetes treatment and obesity care, but one clinical-stage pharma company could be the next breakout star. One of the biggest sensations fueling the healthcare space right now is the medication class of glucagon-like peptide-1 (GLP-1) agonists. Even if you aren't familiar with the term "GLP-1," you've probably heard of Ozempic and Wegovy. Both medications are GLP-1 agonists, used to treat diabetes and obesity, respectively. These treatments have become blockbuster drugs for their mak ...

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts ...

Structure Therapeutics Inc. (NASDAQ:GPCR) was able to report positive results from its phase 2a study using its GLP-1R agonist GSBR-1290 for the treatment of patients with obesity in June 2024. This is an important outcome because it now leads to another milestone for investors to look forward to, which is the initiation of the 36-week phase 2b study using this drug to treat these patients in Q4 of 2024. The scope of this biotech though is its ability to achieve rapid weight loss in a short amount of time a ...

Novartis is taking a more calculated and strategic approach to its growth. There are $200 billion reasons healthcare companies want to produce GLP-1 weight loss drugs. At that size, the market potential is huge, and the opportunities for revenue growth are plentiful. But it also means that competition will be fierce. And with some highly effective treatments already approved and available, the bar is set high for any new drug that wants to take a slice of that lucrative market. Not every company is jumping ...